The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis

The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing‐remitting multiple sclerosis (RRMS) with a significant impact on the approach to modern multiple sclerosis (MS) care. Key learnings and perspectives from the early days of disease mo...

Descripción completa

Detalles Bibliográficos
Autor principal: Madsen, Claus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474703/
https://www.ncbi.nlm.nih.gov/pubmed/28638705
http://dx.doi.org/10.1002/brb3.696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474703/
https://www.ncbi.nlm.nih.gov/pubmed/28638705
http://dx.doi.org/10.1002/brb3.696

Ejemplares similares